Enhanced immunity to intracerebral breast cancer in mice immunized with a cDNA-based vaccine enriched for immunotherapeutic cells

Journal of Immunotherapy

Volumn 31, Issue 1, 2008, Pages 18-27

  Lichtor, Terry ^a   Glick, Roberta P ^a   Feldman, Lisa A ^a   Osawa, Goro ^a   Hardman, Julian ^a   O Sullivan, InSug ^b   Cohen, Edward P ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Brain tumors; cDNA; Gene therapy; Tumor vaccine; Vaccine enrichment

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; DNA VACCINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PLASMID VECTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; TUMOR VACCINE; CANCER VACCINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GAMMA INTERFERON; H 2KB PROTEIN, MOUSE; H-2KB PROTEIN, MOUSE; H2 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TUMOR IMMUNITY; ANIMAL; BRAIN; BRAIN TUMOR; BREAST TUMOR; C3H MOUSE; CELL LINE; CHEMISTRY; CYTOLOGY; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; METASTASIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SURVIVAL; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD4; BRAIN; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FEMALE; FIBROBLASTS; FORKHEAD TRANSCRIPTION FACTORS; H-2 ANTIGENS; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-2; MICE; MICE, INBRED C3H; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSFECTION; TREATMENT OUTCOME;

EID: 40749132210     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318157c64e     Document Type: Article

References (25)

1. Cohen EP. DNA-based vaccines for the treatment of cancer - an experimental model. Trends Mol Med. 2001;7:175-179.
2. Kim TS, Chopra A, O-Sullivan I, et al. Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells. Enrichment of the vaccine for immunotherapeutic cells. J Immunother. 2006;29:261-273.
3. Lichtor T, Glick RP, Tarlock K, et al. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther. 2002;9:464-469.
4. Lichtor T, Glick RP, Lin H, et al. Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer. Cancer Gene Ther. 2005;12:708-714.
5. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294-3302.
6. de Zoeten E, Carr-Brendel V, Markovic D, et al. Treatment of breast cancer with fibroblasts transfected with DNA from breast cancer cells. J Immunol. 1999;162:6934-6941.
7. O-Sullivan I, Ku G, Ertl HCJ, et al. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res. 2002;22:613-622.
8. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
9. + cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother. 2003;52:632-637.
10. Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
11. Restifo NP, Esquivel F, Asher AL, et al. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti tumor immune response. J Immunol. 1991;147:1453-1458.
12. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppressed tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med. 1991;173:889-897.
13. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
14. Mullen CA, Coale MM, Levy AT, et al. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 1992;52:6020-6024.
15. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Nat Acad Sci U S A. 1993;90:3539-3543.
16. Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med. 1993;177:1127-1134.
17. Cavallo F, Pierro FD, Giovarelli M, et al. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 1993;53:5067-5070.
18. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
19. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and down-regulation in melanoma cell lines. J Immunol. 1994;153:1225-1237.
20. Valmori D, Levy F, Miconnet I, et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol. 2000;164:1125-1131.
21. Yu JS, Wei MX, Chiocca EA, et al. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 1993;53:3125-3128.
22. Natsume A, Mizuno M, Ryuke Y, et al. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther. 1999;6:1626-1633.
23. Liu Y, Ehtesham M, Samoto K, et al. In site adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther. 2002;9:9-15.
24. Kim TS, Cohen EP. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res. 1994;54:2531-2535.
25. Whiteside TL, Gambotto A, Albers A, et al. Human tumor derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo. Proc Natl Acad Sci U S A. 2002;99:9415-9420.